Companies BeOne Medicines

BeOne Medicines (BGNE): executive pay, fiscal 2025

Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me BeOne Medicines’s executive pay brief as a PDF

You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

CEO total pay$17,943,521CEO John Oyler · source

Say-on-pay support94.86%Latest vote · source

CEO vs. named peers25th pct.Of 12 peer CEOs

CEO pay, last three years

$17,943,521FY2025

CEO total pay was $17,943,521 in fiscal 2025; the brief holds no earlier figure for this CEO.

FY2025: salary $1,133,000 · bonus $0 · stock awards $11,249,615 · option awards $3,749,967

Executives and directors

Aaron Rosenberg · CFO Chan Lee · General Counsel Lai Wang · President Xiaobin Wu · President

Frequently asked questions

Who was the highest-paid executive at BeOne Medicines in fiscal 2025?

As disclosed, Lai Wang (President, Global Head of Research and Development) was the highest-paid executive at BeOne Medicines in fiscal 2025, with total compensation of $18,319,310.

How does BeOne Medicines's chief executive pay compare to its disclosed peer group?

As disclosed, John Oyler's total compensation ranked at the 25th percentile of BeOne Medicines's disclosed peer group.

How did shareholders vote on BeOne Medicines's executive compensation?

As disclosed, 94.86% of shareholders supported BeOne Medicines's executive compensation in the latest say-on-pay vote.

How much does BeOne Medicines spend in total on board compensation for fiscal 2025?

As disclosed, BeOne Medicines reported total board compensation of $6,972,054 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table

Named executive officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension / NQDC	All other	Total
Lai Wang	$659,492	$0	$15,249,603	$1,749,882	$585,629	$0	$74,704	$18,319,310
President, Global Head of Research and Development
John Oyler	1,133,000	0	11,249,615	3,749,967	1,676,840	0	133,829	17,943,521
Co-Founder, Chairman and Chief Executive Officer
Xiaobin Wu	862,412	0	7,499,831	2,499,932	957,277	0	209,999	12,029,451
President and Chief Operating Officer
Aaron Rosenberg	660,000	0	3,870,957	1,290,337	586,080	0	21,000	6,428,374
Chief Financial Officer
Chan Lee	654,000	0	2,849,678	949,876	580,752	0	21,000	5,055,306
Senior Vice President, General Counsel and Corporate Secretary

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officer	FY2025 total	FY2024 total	FY2023 total	Δ FY2024→2025
Lai Wang	$18,319,310	—	—	—
John Oyler	17,943,521	—	—	—
Xiaobin Wu	12,029,451	—	—	—
Aaron Rosenberg	6,428,374	—	—	—
Chan Lee	5,055,306	—	—	—

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

The goal of our compensation programs is to provide market-based compensation opportunities and align compensation delivery with performance, measured both internally against budgets and externally through long-term shareholder value creation. Our pay philosophy for executive officers emphasizes equity compensation over cash to strengthen executive officers’ alignment with shareholders and ensure that pay delivery is connected to actual company performance.

CEO STI target (% of salary)	—
CEO LTI target (% of salary)	—
Independent consultant	Pay Governance
Clawback policy	true
Anti-hedging	true
Anti-pledging	true

Equity grants and outstanding awards

Grants of plan-based awards — fiscal year 2025

Executive	Award	Grant date	Threshold	Target	Granted	Maximum	Grant-date fair value
Aaron Rosenberg	PSU	2025-06-10	63,681	127,361	—	254,722	$2,580,726
Aaron Rosenberg	RSU	2025-06-10	—	—	63,674	—	1,290,231
Lai Wang	PSU	2025-06-10	86,359	172,718	—	345,436	3,499,798
Lai Wang	RSU	2025-12-31	—	—	427,895	—	9,999,906
Lai Wang	OPTION	2025-06-10	—	—	162,565	—	1,749,882
Chan Lee	PSU	2025-06-10	46,878	93,756	—	187,512	1,899,785
Lai Wang	RSU	2025-06-10	—	—	86,359	—	1,749,899
Chan Lee	RSU	2025-06-10	—	—	46,878	—	949,893
John Oyler	OPTION	2025-06-10	—	—	348,374	—	3,749,967
Chan Lee	OPTION	2025-06-10	—	—	88,244	—	949,876
Aaron Rosenberg	OPTION	2025-06-10	—	—	119,873	—	1,290,337

Vehicle mix — grant-date fair value by award type

Named executive officer	Time-vested (RSU)	Performance-vested (PSU)	Options / SARs	% performance-vested
Aaron Rosenberg	$1,290,231	$2,580,726	$1,290,337	50.0%
Lai Wang	11,749,805	3,499,798	1,749,882	20.6%
Chan Lee	949,893	1,899,785	949,876	50.0%
John Oyler	0	0	3,749,967	0.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Outstanding equity awards at fiscal year-end 2025

Executive	Award	Shares unvested	Exercise price	Market value unvested
Chan Lee	Option	27,846	14.96	—
Chan Lee	RSU	29,003	—	677,800
Chan Lee	RSU	29,874	—	698,155
Wang	RSU	31,304	—	732,486
Chan Lee	PSU	32,695	—	764,082
Chan Lee	RSU	32,799	—	766,513
Aaron Rosenberg	PSU	39,533	—	923,886
Aaron Rosenberg	RSU	40,573	—	948,191
Chan Lee	RSU	46,878	—	1,095,539
Xiaobin Wu	RSU	46,969	—	1,097,666
Wang	RSU	55,029	—	1,286,028
Wang	PSU	56,329	—	1,316,409
Chan Lee	PSU	62,504	—	1,460,718
Aaron Rosenberg	RSU	63,674	—	1,488,061
Wang	RSU	66,833	—	1,561,887
Chan Lee	RSU	73,567	—	1,719,261
Xiaobin Wu	RSU	78,624	—	1,837,443
John Oyler	RSU	83,512	—	1,951,675
Xiaobin Wu	PSU	84,487	—	1,974,461
Aaron Rosenberg	PSU	84,916	—	1,984,487
Wang	RSU	86,359	—	2,018,210
Chan Lee	Option	88,244	20.26	—
Wang	Option	88,647	11.98	—
Aaron Rosenberg	RSU	88,920	—	2,078,060
Chan Lee	Option	93,587	16.41	—
Xiaobin Wu	RSU	100,243	—	2,342,679
Chan Lee	RSU	105,599	—	2,467,849
Wang	PSU	115,154	—	2,691,149
Chan Lee	Option	115,518	12.23	—
John Oyler	RSU	117,936	—	2,756,164
Aaron Rosenberg	Option	119,873	20.26	—
Xiaobin Wu	RSU	123,370	—	2,883,157
Wang	RSU	126,711	—	2,961,236
Aaron Rosenberg	RSU	127,595	—	2,981,895
Xiaobin Wu	Option	132,977	11.98	—
Aaron Rosenberg	Option	142,740	14.06	—
Wang	Option	162,565	20.26	—
John Oyler	PSU	163,488	—	3,820,715
Xiaobin Wu	PSU	164,502	—	3,844,412
John Oyler	RSU	177,827	—	4,155,817
Wang	RSU	181,857	—	4,249,998
John Oyler	RSU	185,055	—	4,324,735
Xiaobin Wu	RSU	190,060	—	4,441,702
Wang	Option	190,424	16.41	—
Wang	Option	198,913	12.23	—
Xiaobin Wu	Option	232,245	20.26	—
John Oyler	Option	236,015	11.98	—
John Oyler	PSU	246,753	—	5,766,618
Xiaobin Wu	RSU	272,805	—	6,375,453
Xiaobin Wu	Option	285,402	16.41	—
Xiaobin Wu	Option	298,376	12.23	—
John Oyler	Option	348,374	20.26	—
John Oyler	RSU	367,848	—	8,596,608
Wang	RSU	427,895	—	9,999,906
John Oyler	Option	506,298	16.41	—
John Oyler	RSU	528,060	—	12,340,762
John Oyler	Option	577,551	12.23	—

Director compensation

Director	Cash fees	Stock awards	Option awards	Non-equity incentive	All other	Total
Dr. Xiaodong WangNot independent	$0	$0	$0	—	$4,249,830	$4,249,830
Anthony C. HooperIndependent · Nominating and Corporate Governance Committee (Chair) · Commercial and Medical Affairs Advisory Committee (Chair) · Audit Committee	128,341	199,834	199,954	—	—	528,129
Shalini SharpIndependent · Audit Committee (Chair) · Nominating and Corporate Governance Committee	125,377	199,834	199,954	—	—	525,165
Dr. Margaret DuganIndependent · Compensation Committee (Chair) · Commercial and Medical Affairs Advisory Committee · Scientific Advisory Committee	115,000	199,834	199,954	—	—	514,788
Dr. Corazon (Corsee) D. SandersIndependent · Audit Committee · Scientific Advisory Committee · Commercial and Medical Affairs Advisory Committee · Not standing for re-election	102,500	199,834	199,954	—	—	502,288
Dr. Alessandro RivaIndependent · Scientific Advisory Committee (Co-Chair) · Nominating and Corporate Governance Committee	95,000	199,834	199,954	—	—	494,788
Dr. Olivier BrandicourtIndependent · Audit Committee · Commercial and Medical Affairs Advisory Committee	92,500	199,834	199,954	—	—	492,288
Ranjeev KrishanaIndependent · Compensation Committee · Commercial and Medical Affairs Advisory Committee · Not standing for re-election	90,000	199,834	199,954	—	—	489,788
Qingqing YiIndependent · Compensation Committee · Scientific Advisory Committee · Not standing for re-election	90,000	199,834	199,954	—	—	489,788
Michael GollerIndependent · Nominating and Corporate Governance Committee · Scientific Advisory Committee · Not standing for re-election	85,000	199,834	199,954	—	—	484,788
John V. OylerEmployee director · Board Chair	—	—	—	—	—	0
Ms. Elizabeth F. MooneyIndependent · Compensation Committee · Newly elected	—	—	—	—	—	—
Dr. Felix J. BakerIndependent · Newly elected	—	—	—	—	—	—
Dr. Charles L. SawyersIndependent · Newly elected	—	—	—	—	—	—

Board fee structure and ownership guideline

Annual cash retainer	$65,000
Annual equity retainer	$400,000
Per board meeting fee	—
Committee chair fees (audit / comp / nom-gov)	35,000 / 30,000 / 20,000
Stock ownership guideline	—

Total cost of the board

Component	FY2025
Cash retainers and fees	$923,718
Equity awards (grant-date value)	$1,798,506
All other compensation	$4,249,830
Total cost of the board	$6,972,054

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names BeOne Medicines as a peer

Companies that benchmark against BGNE

7 companies name BGNE as a compensation peer

The list of companies that name BGNE as a peer is temporarily unavailable — recheck shortly.

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

BMRN BioMarin Pharmaceutical, Inc.AMGN Amgen Inc.GILD Gilead Sciences, Inc.ALNY Alnylam Pharmaceuticals, Inc.UTHR United Therapeutics CorporationMRNA Moderna, Inc.BIIB Biogen Inc.EXEL Exelixis, Inc.REGN Regeneron Pharmaceuticals, Inc.INCY Incyte CorporationVRTX Vertex Pharmaceuticals Inc.NBIX Neurocrine Biosciences, Inc.

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

Rank	Company	FY	Chief executive	Salary	Stock awards	Option awards	Non-equity incentive	Total
1	Exelixis, Inc.	2025	Michael Morrissey	$1,306,040	$30,539,552	$0	$1,382,591	$33,239,183
2	Incyte Corporation	2025	William Meury	647,260	27,509,657	2,573,998	1,300,000	32,085,952
3	Gilead Sciences, Inc.	2025	Daniel O'Day	1,795,192	15,238,402	4,500,060	4,848,120	28,437,198
4	Amgen Inc.	2025	Robert Bradway	1,925,409	12,599,589	5,399,996	3,907,000	24,693,120
5	Biogen Inc.	2025	Christopher Viehbacher	1,727,885	18,368,875	0	3,190,875	23,646,004
6	BioMarin Pharmaceutical, Inc.	2025	Alexander Hardy	1,130,769	16,833,629	1,909,310	1,644,500	21,927,563
7	Vertex Pharmaceuticals Inc.	2025	Reshma Kewalramani	1,600,000	15,002,270	0	4,118,640	21,144,261
8	Moderna, Inc.	2025	Stéphane Bancel	1,677,739	6,897,455	6,897,425	4,302,360	19,932,217
9	United Therapeutics Corporation	2025	Martine Rothblatt	1,545,005	6,067,990	6,075,804	4,281,875	18,038,972
10	BeOne Medicines	2025	John Oyler	1,133,000	11,249,615	3,749,967	1,676,840	17,943,521
11	Alnylam Pharmaceuticals, Inc.	2025	Yvonne Greenstreet	1,404,200	5,512,500	4,363,380	3,562,500	14,867,600
12	Neurocrine Biosciences, Inc.	2025	Kyle Gano	920,000	5,750,023	5,750,006	0	13,448,935
13	Regeneron Pharmaceuticals, Inc.	2025	Leonard Schleifer	1,979,922	—	—	3,682,655	7,280,549

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Incentive design against the same peers

Company	Annual incentive payout	Long-term vehicle mix	PSU measures include TSR	Compensation consultant
BeOne Medicines	not disclosed	PSU 50 · Option 25 · RSU 25	No	Pay Governance
Alnylam Pharmaceuticals, Inc.	200%	PSU 50 · RSU 25 · Option 25	No	Pay Governance
Amgen Inc.	136.0%	PSU 50 · Options 30 · RSU 20	Yes — relative TSR	Frederic W. Cook & Co., Inc. (FW Cook)
Biogen Inc.	127%	PSU 60 · RSU 40	Yes	Pay Governance
BioMarin Pharmaceutical, Inc.	130%	PSU 66 · RSU 21 · Options 13	Yes — Relative TSR	Aon Human Capital Solutions
Exelixis, Inc.	105%	PSU 50 · RSU 50	Yes — 2025 Relative TSR Goal	Aon
Gilead Sciences, Inc.	180%	PSU 50 · Option 25 · RSU 25	Yes — Relative TSR	FW Cook
Incyte Corporation	138.6%	PSU 60 · RSU 20 · Option 20	Yes — relative total shareholder return (TSR)	Aon
Moderna, Inc.	170%	PSU 50 · Options 50	No	Pay Governance LLC
Neurocrine Biosciences, Inc.	105%	Option 50 · PRSU 30 · RSU 20	No	Frederic W. Cook & Co., Inc.
Regeneron Pharmaceuticals, Inc.	155%	Options 60 · RSU 40	not disclosed	Pay Governance LLC
United Therapeutics Corporation	221%	PSO 50 · PSU 50	No	Aon
Vertex Pharmaceuticals Inc.	not disclosed	PSU 55 · RSU 45	No	Pearl Meyer

Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.

Say-on-pay history and pay ratio

Meeting year	Meeting date	For	Against	Abstain	Support	Outcome
2026	2026-06-11	975,327,100	52,877,460	32,815,949	94.86%	Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting year	Meeting date	Approval — company’s computation
2026	2026-06-11	94.86%^a

a. Approved under the standard stated in the filing — “Advisory Vote on the Compensation of the Named Executive Officers Vote Required and Board of Directors' Recommendation Approval of Proposal 10 requires the affirmative vote of a simple majority of the votes cast at the Annual Meeting. || Abstentions: Broker non-votes, blank ballots, invalid ballots and abstentions with respect to Proposal 10 will not be treated as votes cast for this purpose and, therefore, will not affect the outcome of the vote.”.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

Insider	Role	Transaction date	Code	Shares	Price	Value	Security	Source
Chan Lee	SVP, General Counsel	2026-05-13	A	98	$159	$15,585	Common	Form 4 ↗
Dividend-equivalent accruals		2026-05-13	—	4,316	—	—	1 insider, 3 accrual rows
Chan Lee	SVP, General Counsel	2026-05-13	A	101	194	19,641	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-05-13	D	332	311	103,159	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-05-13	A	133	213	28,372	Common	Form 4 ↗
Dr. Alessandro Riva	Director	2026-05-22	D	212	310	65,617	Common	Form 4 ↗
BAKER BROS. ADVISORS LP	Director	2026-05-22	D	2,756	24	65,567	Common	Form 4 ↗
Dr. Corazon (Corsee) D. Sanders	Director	2026-05-22	D	212	310	65,633	Common	Form 4 ↗
BAKER BROS. ADVISORS LP	Director	2026-05-22	D	2,743	24	65,424	Common	Form 4 ↗
Dr. Margaret Dugan	Director	2026-05-22	D	212	310	65,636	Common	Form 4 ↗
BAKER BROS. ADVISORS LP	Director	2026-05-22	D	2,756	24	65,567	Common	Form 4 ↗
BAKER BROS. ADVISORS LP	Director	2026-05-22	D	2,743	24	65,424	Common	Form 4 ↗
Qingqing Yi	Director	2026-06-01	D	235	279	65,596	Common	Form 4 ↗
Xiaobin Wu	President and COO	2026-06-08	D	40	271	10,822	Common	Form 4 ↗
Lai Wang	President, Global Head of R&D	2026-06-08	D	40	271	10,829	Common	Form 4 ↗
John Oyler	Director	2026-06-08	D	3,820	270	1,032,870	Common	Form 4 ↗
Lai Wang	President, Global Head of R&D	2026-06-08	D	1,327	269	357,418	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-06-08	D	160	271	43,401	Common	Form 4 ↗
Titus B. Ball	Principal Accounting Officer	2026-06-08	D	36	272	9,795	Common	Form 4 ↗
Xiaobin Wu	President and COO	2026-06-08	D	1,444	269	388,916	Common	Form 4 ↗
Titus B. Ball	Principal Accounting Officer	2026-06-08	D	100	271	27,106	Common	Form 4 ↗
John Oyler	Director	2026-06-08	D	1,120	271	303,678	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-06-08	D	711	270	192,138	Common	Form 4 ↗
John Oyler	Director	2026-06-11	D	149	259	38,563	Common	Form 4 ↗
John Oyler	Director	2026-06-11	A	344,669	0	0	Derivative, Class A Common	Form 4 ↗
John Oyler	Director	2026-06-11	D	741	256	189,865	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-06-11	D	428	258	110,268	Common	Form 4 ↗
Xiaobin Wu	President and COO	2026-06-11	D	626	261	163,512	Common	Form 4 ↗
Titus B. Ball	Principal Accounting Officer	2026-06-11	D	120	258	30,904	Common	Form 4 ↗
BAKER BROS. ADVISORS LP	Director	2026-06-11	A	18,980	0	0	Common	Form 4 ↗
Xiaodong Wang	Director	2026-06-11	A	193,492	0	0	Derivative, Class A Common	Form 4 ↗
Titus B. Ball	Principal Accounting Officer	2026-06-11	D	49	256	12,563	Common	Form 4 ↗
Dr. Alessandro Riva	Director	2026-06-11	A	18,980	0	0	Common	Form 4 ↗
Ms. Elizabeth F. Mooney	Director	2026-06-11	A	18,980	0	0	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-06-11	A	87,308	0	0	Derivative, Class A Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-06-11	A	45,071	0	0	Common	Form 4 ↗
Aaron Rosenberg	Chief Financial Officer	2026-06-11	D	631	258	162,637	Common	Form 4 ↗
Titus B. Ball	Principal Accounting Officer	2026-06-11	A	31,213	0	0	Common	Form 4 ↗
Anthony C. Hooper	Director	2026-06-11	A	18,980	0	0	Common	Form 4 ↗
BAKER BROS. ADVISORS LP	Director	2026-06-11	A	18,980	0	0	Common	Form 4 ↗
Dr. Olivier Brandicourt	Director	2026-06-11	A	18,980	0	0	Common	Form 4 ↗
Lai Wang	President, Global Head of R&D	2026-06-11	A	229,775	0	0	Derivative, Class A Common	Form 4 ↗
Lai Wang	President, Global Head of R&D	2026-06-11	A	118,625	0	0	Common	Form 4 ↗
Xiaobin Wu	President and COO	2026-06-11	A	118,625	0	0	Common	Form 4 ↗
Aaron Rosenberg	Chief Financial Officer	2026-06-11	A	137,865	0	0	Derivative, Class A Common	Form 4 ↗
Aaron Rosenberg	Chief Financial Officer	2026-06-11	A	71,175	0	0	Common	Form 4 ↗
Dr. Charles L. Sawyers	Director	2026-06-11	A	18,980	0	0	Common	Form 4 ↗
John Oyler	Director	2026-06-11	D	859	258	221,271	Common	Form 4 ↗
John Oyler	Director	2026-06-11	A	177,931	0	0	Common	Form 4 ↗
Lai Wang	President, Global Head of R&D	2026-06-11	D	756	261	197,318	Common	Form 4 ↗
Shalini Sharp	Director	2026-06-11	A	18,980	0	0	Common	Form 4 ↗
Xiaodong Wang	Director	2026-06-11	A	99,892	0	0	Common	Form 4 ↗
Dr. Margaret Dugan	Director	2026-06-11	A	18,980	0	0	Common	Form 4 ↗
Xiaobin Wu	President and COO	2026-06-11	A	229,775	0	0	Derivative, Class A Common	Form 4 ↗
John Oyler	Director	2026-06-11	D	200	258	51,656	Common	Form 4 ↗
John Oyler	Director	2026-06-16	D	1,710	266	454,835	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-06-16	D	590	266	156,925	Common	Form 4 ↗
Lai Wang	President, Global Head of R&D	2026-06-16	D	1,169	265	310,236	Common	Form 4 ↗
John Oyler	Director	2026-06-16	D	333	267	88,809	Common	Form 4 ↗
John Oyler	Director	2026-06-16	D	1,650	265	437,042	Common	Form 4 ↗
Xiaobin Wu	President and COO	2026-06-16	D	1,357	267	361,997	Common	Form 4 ↗
Xiaobin Wu	President and COO	2026-06-23	D	1,292	276	356,927	Common	Form 4 ↗
John Oyler	Director	2026-06-23	D	1,290	274	353,613	Common	Form 4 ↗
Lai Wang	President, Global Head of R&D	2026-06-23	D	1,068	277	295,553	Common	Form 4 ↗
John Oyler	Director	2026-06-23	D	320	275	88,030	Common	Form 4 ↗
John Oyler	Director	2026-06-23	D	1,800	273	491,949	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-08	D	2,548	0	0	Derivative, Class A Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-08	D	3,458	0	0	Derivative, Class A Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-08	D	2,626	0	0	Derivative, Class A Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-08	D	664	302	200,833	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-08	A	196	159	31,170	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-08	A	266	213	56,743	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-08	A	202	194	39,283	Common	Form 4 ↗
John Oyler	Director	2026-07-10	D	18	303	5,455	Common	Form 4 ↗
John Oyler	Director	2026-07-10	D	136	302	41,098	Common	Form 4 ↗
John Oyler	Director	2026-07-10	D	152,074	0	0	Derivative, Class A Common	Form 4 ↗
John Oyler	Director	2026-07-10	D	150	301	45,177	Common	Form 4 ↗
John Oyler	Director	2026-07-10	D	5,143	299	1,537,429	Common	Form 4 ↗
John Oyler	Director	2026-07-10	D	3,074	298	917,133	Common	Form 4 ↗
John Oyler	Director	2026-07-10	D	1,314	297	390,561	Common	Form 4 ↗
John Oyler	Director	2026-07-10	A	11,698	37	431,656	Common	Form 4 ↗
John Oyler	Director	2026-07-10	D	370	300	111,044	Common	Form 4 ↗
John Oyler	Director	2026-07-10	D	1,493	296	442,028	Common	Form 4 ↗
John Oyler	Director	2026-07-13	D	320	307	98,370	Common	Form 4 ↗
John Oyler	Director	2026-07-13	D	4,584	303	1,387,981	Common	Form 4 ↗
John Oyler	Director	2026-07-13	D	846	306	258,508	Common	Form 4 ↗
John Oyler	Director	2026-07-13	D	630,760	0	0	Derivative, Class A Common	Form 4 ↗
John Oyler	Director	2026-07-13	D	7,240	307	2,221,409	Common	Form 4 ↗
John Oyler	Director	2026-07-13	D	26,294	304	7,988,777	Common	Form 4 ↗
John Oyler	Director	2026-07-13	D	798	302	240,945	Common	Form 4 ↗
John Oyler	Director	2026-07-13	A	48,520	37	1,790,388	Common	Form 4 ↗
John Oyler	Director	2026-07-13	D	8,438	305	2,570,892	Common	Form 4 ↗
John Oyler	Director	2026-07-14	D	45,895	306	14,053,627	Common	Form 4 ↗
John Oyler	Director	2026-07-14	D	7,834	308	2,409,534	Common	Form 4 ↗
John Oyler	Director	2026-07-14	D	39,090	305	11,923,259	Common	Form 4 ↗
John Oyler	Director	2026-07-14	D	472,134	0	0	Derivative, Class A Common	Form 4 ↗
John Oyler	Director	2026-07-14	D	1,264,666	0	0	Derivative, Class A Common	Form 4 ↗
John Oyler	Director	2026-07-14	D	40,781	307	12,517,112	Common	Form 4 ↗
John Oyler	Director	2026-07-14	A	97,282	37	3,589,706	Common	Form 4 ↗
John Oyler	Director	2026-07-14	D	8,122	304	2,468,490	Common	Form 4 ↗
John Oyler	Director	2026-07-14	A	36,318	100	3,633,253	Common	Form 4 ↗
John Oyler	Director	2026-07-14	D	4,139	303	1,254,401	Common	Form 4 ↗
John Oyler	Director	2026-07-15	D	48,657	313	15,222,746	Common	Form 4 ↗
John Oyler	Director	2026-07-15	D	6,067	310	1,880,892	Common	Form 4 ↗
John Oyler	Director	2026-07-15	D	55,575	0	0	Derivative, Class A Common	Form 4 ↗
John Oyler	Director	2026-07-15	D	7,640	314	2,395,746	Common	Form 4 ↗
John Oyler	Director	2026-07-15	D	996,801	0	0	Derivative, Class A Common	Form 4 ↗
John Oyler	Director	2026-07-15	D	462,865	0	0	Derivative, Class A Common	Form 4 ↗
John Oyler	Director	2026-07-15	D	12,857	312	4,007,685	Common	Form 4 ↗
John Oyler	Director	2026-07-15	D	41,336	311	12,852,305	Common	Form 4 ↗
John Oyler	Director	2026-07-15	A	4,275	160	685,710	Common	Form 4 ↗
John Oyler	Director	2026-07-15	A	76,677	170	13,002,886	Common	Form 4 ↗
John Oyler	Director	2026-07-15	A	35,605	100	3,561,924	Common	Form 4 ↗
John Oyler	Director	2026-07-16	D	4,881	314	1,533,011	Common	Form 4 ↗
John Oyler	Director	2026-07-16	D	19,752	316	6,241,632	Common	Form 4 ↗
John Oyler	Director	2026-07-16	D	1,560	323	503,424	Common	Form 4 ↗
John Oyler	Director	2026-07-16	D	1,254,513	0	0	Derivative, Class A Common	Form 4 ↗
John Oyler	Director	2026-07-16	D	520	324	168,265	Common	Form 4 ↗
John Oyler	Director	2026-07-16	D	13,109	322	4,216,021	Common	Form 4 ↗
John Oyler	Director	2026-07-16	D	15,097	320	4,830,934	Common	Form 4 ↗
John Oyler	Director	2026-07-16	D	6,402	319	2,039,353	Common	Form 4 ↗
John Oyler	Director	2026-07-16	D	42,798	318	13,600,721	Common	Form 4 ↗
John Oyler	Director	2026-07-16	D	32,224	317	10,209,121	Common	Form 4 ↗
John Oyler	Director	2026-07-16	D	233	312	72,691	Common	Form 4 ↗
John Oyler	Director	2026-07-16	D	911,248	0	0	Derivative, Class A Common	Form 4 ↗
John Oyler	Director	2026-07-16	D	9,516	315	2,994,988	Common	Form 4 ↗
John Oyler	Director	2026-07-16	A	70,096	120	8,408,716	Common	Form 4 ↗
John Oyler	Director	2026-07-16	A	96,501	160	15,478,760	Common	Form 4 ↗
John Oyler	Director	2026-07-16	D	20,505	321	6,582,064	Common	Form 4 ↗
John Oyler	Director	2026-07-17	D	51	315	16,068	Common	Form 4 ↗
John Oyler	Director	2026-07-17	D	840,164	0	0	Derivative, Class A Common	Form 4 ↗
John Oyler	Director	2026-07-17	D	740	314	232,597	Common	Form 4 ↗
John Oyler	Director	2026-07-17	D	14,915	313	4,671,198	Common	Form 4 ↗
John Oyler	Director	2026-07-17	D	35,829	312	11,184,911	Common	Form 4 ↗
John Oyler	Director	2026-07-17	D	4,833	310	1,500,015	Common	Form 4 ↗
John Oyler	Director	2026-07-17	D	680	309	210,157	Common	Form 4 ↗
John Oyler	Director	2026-07-17	D	1,440	305	439,486	Common	Form 4 ↗
John Oyler	Director	2026-07-17	D	5,543	311	1,726,218	Common	Form 4 ↗
John Oyler	Director	2026-07-17	D	597	307	183,258	Common	Form 4 ↗
John Oyler	Director	2026-07-17	A	64,628	120	7,752,775	Common	Form 4 ↗
John Oyler	Director	2026-07-20	D	280	318	89,124	Common	Form 4 ↗
John Oyler	Director	2026-07-20	D	1,850	314	580,732	Common	Form 4 ↗
John Oyler	Director	2026-07-20	D	523	316	165,339	Common	Form 4 ↗
John Oyler	Director	2026-07-20	D	1,512	315	476,678	Common	Form 4 ↗
John Oyler	Director	2026-07-20	D	14,326	313	4,483,433	Common	Form 4 ↗
John Oyler	Director	2026-07-20	D	15,499	312	4,840,115	Common	Form 4 ↗
John Oyler	Director	2026-07-20	A	33,990	120	4,077,440	Common	Form 4 ↗
John Oyler	Director	2026-07-20	D	2,907	312	906,389	Common	Form 4 ↗
John Oyler	Director	2026-07-20	D	6,273	311	1,949,310	Common	Form 4 ↗
John Oyler	Director	2026-07-20	D	441,870	0	0	Derivative, Class A Common	Form 4 ↗
John Oyler	Director	2026-07-20	D	5,146	310	1,595,678	Common	Form 4 ↗
John Oyler	Director	2026-07-21	D	7,842	318	2,496,997	Common	Form 4 ↗
John Oyler	Director	2026-07-21	D	15,379	316	4,863,766	Common	Form 4 ↗
John Oyler	Director	2026-07-21	D	2,340	320	748,936	Common	Form 4 ↗
John Oyler	Director	2026-07-21	D	15,807	319	5,047,019	Common	Form 4 ↗
John Oyler	Director	2026-07-21	D	20,029	317	6,347,340	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-22	D	6,370	0	0	Derivative, Class A Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-22	D	8,645	0	0	Derivative, Class A Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-22	D	6,682	0	0	Derivative, Class A Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-22	D	1,669	325	542,425	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-22	A	490	159	77,925	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-22	A	665	213	141,858	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-22	A	514	194	99,958	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-30	D	1,044	324	337,932	Common	Form 4 ↗
Aaron Rosenberg	Chief Financial Officer	2026-08-03	D	1,157	313	361,811	Common	Form 4 ↗
John Oyler	Director	2026-08-10	D	6,717	355	2,383,028	Common	Form 4 ↗
John Oyler	Director	2026-08-10	D	15,869	358	5,675,864	Common	Form 4 ↗
John Oyler	Director	2026-08-10	D	3,476	356	1,236,261	Common	Form 4 ↗
John Oyler	Director	2026-08-10	D	12,418	357	4,428,482	Common	Form 4 ↗
John Oyler	Director	2026-08-10	D	3,680	361	1,327,130	Common	Form 4 ↗
John Oyler	Director	2026-08-10	D	21,254	360	7,640,826	Common	Form 4 ↗
John Oyler	Director	2026-08-10	D	45,044	359	16,157,076	Common	Form 4 ↗
John Oyler	Director	2026-08-10	D	3,673	353	1,297,741	Common	Form 4 ↗
John Oyler	Director	2026-08-10	D	2,813	352	989,603	Common	Form 4 ↗
John Oyler	Director	2026-08-10	D	67	350	23,450	Common	Form 4 ↗
John Oyler	Director	2026-08-11	D	13,403	363	4,871,344	Common	Form 4 ↗
John Oyler	Director	2026-08-11	D	13,695	359	4,920,844	Common	Form 4 ↗
John Oyler	Director	2026-08-11	D	3,176	365	1,160,079	Common	Form 4 ↗
John Oyler	Director	2026-08-11	D	4	367	1,468	Common	Form 4 ↗
John Oyler	Director	2026-08-11	D	1,200	366	439,574	Common	Form 4 ↗
John Oyler	Director	2026-08-11	D	11,568	362	4,191,548	Common	Form 4 ↗
John Oyler	Director	2026-08-11	D	14,569	361	5,266,268	Common	Form 4 ↗
John Oyler	Director	2026-08-11	D	8,081	360	2,911,849	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-08-11	D	10,556	0	0	Derivative, Class A Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-08-11	A	796	159	126,588	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-08-11	D	10,348	0	0	Derivative, Class A Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-08-11	D	13,754	0	0	Derivative, Class A Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-08-11	D	2,666	360	959,760	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-08-11	A	1,058	213	225,693	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-08-11	A	812	194	157,910	Common	Form 4 ↗
John Oyler	Director	2026-08-11	D	5,211	364	1,898,442	Common	Form 4 ↗
John Oyler	Director	2026-08-12	D	15,396	358	5,506,147	Common	Form 4 ↗
John Oyler	Director	2026-08-12	D	1,980	355	702,320	Common	Form 4 ↗
John Oyler	Director	2026-08-12	D	14,102	359	5,064,252	Common	Form 4 ↗
John Oyler	Director	2026-08-12	D	20,899	358	7,490,448	Common	Form 4 ↗
John Oyler	Director	2026-08-12	D	2,515	356	896,426	Common	Form 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 198 transactions

Insider	Role	Transaction date	Code	Shares	Price	Value	Security	Source
Chan Lee	SVP, General Counsel	2026-05-13	A	98	$159	$15,585	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-05-13	D	1,729	0	0	Derivative, Class A Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-05-13	D	1,313	0	0	Derivative, Class A Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-05-13	A	101	194	19,641	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-05-13	D	1,274	0	0	Derivative, Class A Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-05-13	D	332	311	103,159	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-05-13	A	133	213	28,372	Common	Form 4 ↗
Dr. Alessandro Riva	Director	2026-05-22	D	212	310	65,617	Common	Form 4 ↗
BAKER BROS. ADVISORS LP	Director	2026-05-22	D	2,756	24	65,567	Common	Form 4 ↗
Dr. Corazon (Corsee) D. Sanders	Director	2026-05-22	D	212	310	65,633	Common	Form 4 ↗
BAKER BROS. ADVISORS LP	Director	2026-05-22	D	2,743	24	65,424	Common	Form 4 ↗
Dr. Margaret Dugan	Director	2026-05-22	D	212	310	65,636	Common	Form 4 ↗
BAKER BROS. ADVISORS LP	Director	2026-05-22	D	2,756	24	65,567	Common	Form 4 ↗
BAKER BROS. ADVISORS LP	Director	2026-05-22	D	2,743	24	65,424	Common	Form 4 ↗
Qingqing Yi	Director	2026-06-01	D	235	279	65,596	Common	Form 4 ↗
Xiaobin Wu	President and COO	2026-06-08	D	40	271	10,822	Common	Form 4 ↗
Lai Wang	President, Global Head of R&D	2026-06-08	D	40	271	10,829	Common	Form 4 ↗
John Oyler	Director	2026-06-08	D	3,820	270	1,032,870	Common	Form 4 ↗
Lai Wang	President, Global Head of R&D	2026-06-08	D	1,327	269	357,418	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-06-08	D	160	271	43,401	Common	Form 4 ↗
Titus B. Ball	Principal Accounting Officer	2026-06-08	D	36	272	9,795	Common	Form 4 ↗
Xiaobin Wu	President and COO	2026-06-08	D	1,444	269	388,916	Common	Form 4 ↗
Titus B. Ball	Principal Accounting Officer	2026-06-08	D	100	271	27,106	Common	Form 4 ↗
John Oyler	Director	2026-06-08	D	1,120	271	303,678	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-06-08	D	711	270	192,138	Common	Form 4 ↗
John Oyler	Director	2026-06-11	D	149	259	38,563	Common	Form 4 ↗
John Oyler	Director	2026-06-11	A	344,669	0	0	Derivative, Class A Common	Form 4 ↗
John Oyler	Director	2026-06-11	D	741	256	189,865	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-06-11	D	428	258	110,268	Common	Form 4 ↗
Xiaobin Wu	President and COO	2026-06-11	D	626	261	163,512	Common	Form 4 ↗
Titus B. Ball	Principal Accounting Officer	2026-06-11	D	120	258	30,904	Common	Form 4 ↗
BAKER BROS. ADVISORS LP	Director	2026-06-11	A	18,980	0	0	Common	Form 4 ↗
Xiaodong Wang	Director	2026-06-11	A	193,492	0	0	Derivative, Class A Common	Form 4 ↗
Titus B. Ball	Principal Accounting Officer	2026-06-11	D	49	256	12,563	Common	Form 4 ↗
Dr. Alessandro Riva	Director	2026-06-11	A	18,980	0	0	Common	Form 4 ↗
Ms. Elizabeth F. Mooney	Director	2026-06-11	A	18,980	0	0	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-06-11	A	87,308	0	0	Derivative, Class A Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-06-11	A	45,071	0	0	Common	Form 4 ↗
Aaron Rosenberg	Chief Financial Officer	2026-06-11	D	631	258	162,637	Common	Form 4 ↗
Titus B. Ball	Principal Accounting Officer	2026-06-11	A	31,213	0	0	Common	Form 4 ↗
Anthony C. Hooper	Director	2026-06-11	A	18,980	0	0	Common	Form 4 ↗
BAKER BROS. ADVISORS LP	Director	2026-06-11	A	18,980	0	0	Common	Form 4 ↗
Dr. Olivier Brandicourt	Director	2026-06-11	A	18,980	0	0	Common	Form 4 ↗
Lai Wang	President, Global Head of R&D	2026-06-11	A	229,775	0	0	Derivative, Class A Common	Form 4 ↗
Lai Wang	President, Global Head of R&D	2026-06-11	A	118,625	0	0	Common	Form 4 ↗
Xiaobin Wu	President and COO	2026-06-11	A	118,625	0	0	Common	Form 4 ↗
Aaron Rosenberg	Chief Financial Officer	2026-06-11	A	137,865	0	0	Derivative, Class A Common	Form 4 ↗
Aaron Rosenberg	Chief Financial Officer	2026-06-11	A	71,175	0	0	Common	Form 4 ↗
Dr. Charles L. Sawyers	Director	2026-06-11	A	18,980	0	0	Common	Form 4 ↗
John Oyler	Director	2026-06-11	D	859	258	221,271	Common	Form 4 ↗
John Oyler	Director	2026-06-11	A	177,931	0	0	Common	Form 4 ↗
Lai Wang	President, Global Head of R&D	2026-06-11	D	756	261	197,318	Common	Form 4 ↗
Shalini Sharp	Director	2026-06-11	A	18,980	0	0	Common	Form 4 ↗
Xiaodong Wang	Director	2026-06-11	A	99,892	0	0	Common	Form 4 ↗
Dr. Margaret Dugan	Director	2026-06-11	A	18,980	0	0	Common	Form 4 ↗
Xiaobin Wu	President and COO	2026-06-11	A	229,775	0	0	Derivative, Class A Common	Form 4 ↗
John Oyler	Director	2026-06-11	D	200	258	51,656	Common	Form 4 ↗
John Oyler	Director	2026-06-16	D	1,710	266	454,835	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-06-16	D	590	266	156,925	Common	Form 4 ↗
Lai Wang	President, Global Head of R&D	2026-06-16	D	1,169	265	310,236	Common	Form 4 ↗
John Oyler	Director	2026-06-16	D	333	267	88,809	Common	Form 4 ↗
John Oyler	Director	2026-06-16	D	1,650	265	437,042	Common	Form 4 ↗
Xiaobin Wu	President and COO	2026-06-16	D	1,357	267	361,997	Common	Form 4 ↗
Xiaobin Wu	President and COO	2026-06-23	D	1,292	276	356,927	Common	Form 4 ↗
John Oyler	Director	2026-06-23	D	1,290	274	353,613	Common	Form 4 ↗
Lai Wang	President, Global Head of R&D	2026-06-23	D	1,068	277	295,553	Common	Form 4 ↗
John Oyler	Director	2026-06-23	D	320	275	88,030	Common	Form 4 ↗
John Oyler	Director	2026-06-23	D	1,800	273	491,949	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-08	D	2,548	0	0	Derivative, Class A Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-08	D	3,458	0	0	Derivative, Class A Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-08	D	2,626	0	0	Derivative, Class A Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-08	D	664	302	200,833	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-08	A	196	159	31,170	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-08	A	266	213	56,743	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-08	A	202	194	39,283	Common	Form 4 ↗
John Oyler	Director	2026-07-10	D	18	303	5,455	Common	Form 4 ↗
John Oyler	Director	2026-07-10	D	136	302	41,098	Common	Form 4 ↗
John Oyler	Director	2026-07-10	D	152,074	0	0	Derivative, Class A Common	Form 4 ↗
John Oyler	Director	2026-07-10	D	150	301	45,177	Common	Form 4 ↗
John Oyler	Director	2026-07-10	D	5,143	299	1,537,429	Common	Form 4 ↗
John Oyler	Director	2026-07-10	D	3,074	298	917,133	Common	Form 4 ↗
John Oyler	Director	2026-07-10	D	1,314	297	390,561	Common	Form 4 ↗
John Oyler	Director	2026-07-10	A	11,698	37	431,656	Common	Form 4 ↗
John Oyler	Director	2026-07-10	D	370	300	111,044	Common	Form 4 ↗
John Oyler	Director	2026-07-10	D	1,493	296	442,028	Common	Form 4 ↗
John Oyler	Director	2026-07-13	D	320	307	98,370	Common	Form 4 ↗
John Oyler	Director	2026-07-13	D	4,584	303	1,387,981	Common	Form 4 ↗
John Oyler	Director	2026-07-13	D	846	306	258,508	Common	Form 4 ↗
John Oyler	Director	2026-07-13	D	630,760	0	0	Derivative, Class A Common	Form 4 ↗
John Oyler	Director	2026-07-13	D	7,240	307	2,221,409	Common	Form 4 ↗
John Oyler	Director	2026-07-13	D	26,294	304	7,988,777	Common	Form 4 ↗
John Oyler	Director	2026-07-13	D	798	302	240,945	Common	Form 4 ↗
John Oyler	Director	2026-07-13	A	48,520	37	1,790,388	Common	Form 4 ↗
John Oyler	Director	2026-07-13	D	8,438	305	2,570,892	Common	Form 4 ↗
John Oyler	Director	2026-07-14	D	45,895	306	14,053,627	Common	Form 4 ↗
John Oyler	Director	2026-07-14	D	7,834	308	2,409,534	Common	Form 4 ↗
John Oyler	Director	2026-07-14	D	39,090	305	11,923,259	Common	Form 4 ↗
John Oyler	Director	2026-07-14	D	472,134	0	0	Derivative, Class A Common	Form 4 ↗
John Oyler	Director	2026-07-14	D	1,264,666	0	0	Derivative, Class A Common	Form 4 ↗
John Oyler	Director	2026-07-14	D	40,781	307	12,517,112	Common	Form 4 ↗
John Oyler	Director	2026-07-14	A	97,282	37	3,589,706	Common	Form 4 ↗
John Oyler	Director	2026-07-14	D	8,122	304	2,468,490	Common	Form 4 ↗
John Oyler	Director	2026-07-14	A	36,318	100	3,633,253	Common	Form 4 ↗
John Oyler	Director	2026-07-14	D	4,139	303	1,254,401	Common	Form 4 ↗
John Oyler	Director	2026-07-15	D	48,657	313	15,222,746	Common	Form 4 ↗
John Oyler	Director	2026-07-15	D	6,067	310	1,880,892	Common	Form 4 ↗
John Oyler	Director	2026-07-15	D	55,575	0	0	Derivative, Class A Common	Form 4 ↗
John Oyler	Director	2026-07-15	D	7,640	314	2,395,746	Common	Form 4 ↗
John Oyler	Director	2026-07-15	D	996,801	0	0	Derivative, Class A Common	Form 4 ↗
John Oyler	Director	2026-07-15	D	462,865	0	0	Derivative, Class A Common	Form 4 ↗
John Oyler	Director	2026-07-15	D	12,857	312	4,007,685	Common	Form 4 ↗
John Oyler	Director	2026-07-15	D	41,336	311	12,852,305	Common	Form 4 ↗
John Oyler	Director	2026-07-15	A	4,275	160	685,710	Common	Form 4 ↗
John Oyler	Director	2026-07-15	A	76,677	170	13,002,886	Common	Form 4 ↗
John Oyler	Director	2026-07-15	A	35,605	100	3,561,924	Common	Form 4 ↗
John Oyler	Director	2026-07-16	D	4,881	314	1,533,011	Common	Form 4 ↗
John Oyler	Director	2026-07-16	D	19,752	316	6,241,632	Common	Form 4 ↗
John Oyler	Director	2026-07-16	D	1,560	323	503,424	Common	Form 4 ↗
John Oyler	Director	2026-07-16	D	1,254,513	0	0	Derivative, Class A Common	Form 4 ↗
John Oyler	Director	2026-07-16	D	520	324	168,265	Common	Form 4 ↗
John Oyler	Director	2026-07-16	D	13,109	322	4,216,021	Common	Form 4 ↗
John Oyler	Director	2026-07-16	D	15,097	320	4,830,934	Common	Form 4 ↗
John Oyler	Director	2026-07-16	D	6,402	319	2,039,353	Common	Form 4 ↗
John Oyler	Director	2026-07-16	D	42,798	318	13,600,721	Common	Form 4 ↗
John Oyler	Director	2026-07-16	D	32,224	317	10,209,121	Common	Form 4 ↗
John Oyler	Director	2026-07-16	D	233	312	72,691	Common	Form 4 ↗
John Oyler	Director	2026-07-16	D	911,248	0	0	Derivative, Class A Common	Form 4 ↗
John Oyler	Director	2026-07-16	D	9,516	315	2,994,988	Common	Form 4 ↗
John Oyler	Director	2026-07-16	A	70,096	120	8,408,716	Common	Form 4 ↗
John Oyler	Director	2026-07-16	A	96,501	160	15,478,760	Common	Form 4 ↗
John Oyler	Director	2026-07-16	D	20,505	321	6,582,064	Common	Form 4 ↗
John Oyler	Director	2026-07-17	D	51	315	16,068	Common	Form 4 ↗
John Oyler	Director	2026-07-17	D	840,164	0	0	Derivative, Class A Common	Form 4 ↗
John Oyler	Director	2026-07-17	D	740	314	232,597	Common	Form 4 ↗
John Oyler	Director	2026-07-17	D	14,915	313	4,671,198	Common	Form 4 ↗
John Oyler	Director	2026-07-17	D	35,829	312	11,184,911	Common	Form 4 ↗
John Oyler	Director	2026-07-17	D	4,833	310	1,500,015	Common	Form 4 ↗
John Oyler	Director	2026-07-17	D	680	309	210,157	Common	Form 4 ↗
John Oyler	Director	2026-07-17	D	1,440	305	439,486	Common	Form 4 ↗
John Oyler	Director	2026-07-17	D	5,543	311	1,726,218	Common	Form 4 ↗
John Oyler	Director	2026-07-17	D	597	307	183,258	Common	Form 4 ↗
John Oyler	Director	2026-07-17	A	64,628	120	7,752,775	Common	Form 4 ↗
John Oyler	Director	2026-07-20	D	280	318	89,124	Common	Form 4 ↗
John Oyler	Director	2026-07-20	D	1,850	314	580,732	Common	Form 4 ↗
John Oyler	Director	2026-07-20	D	523	316	165,339	Common	Form 4 ↗
John Oyler	Director	2026-07-20	D	1,512	315	476,678	Common	Form 4 ↗
John Oyler	Director	2026-07-20	D	14,326	313	4,483,433	Common	Form 4 ↗
John Oyler	Director	2026-07-20	D	15,499	312	4,840,115	Common	Form 4 ↗
John Oyler	Director	2026-07-20	A	33,990	120	4,077,440	Common	Form 4 ↗
John Oyler	Director	2026-07-20	D	2,907	312	906,389	Common	Form 4 ↗
John Oyler	Director	2026-07-20	D	6,273	311	1,949,310	Common	Form 4 ↗
John Oyler	Director	2026-07-20	D	441,870	0	0	Derivative, Class A Common	Form 4 ↗
John Oyler	Director	2026-07-20	D	5,146	310	1,595,678	Common	Form 4 ↗
John Oyler	Director	2026-07-21	D	7,842	318	2,496,997	Common	Form 4 ↗
John Oyler	Director	2026-07-21	D	15,379	316	4,863,766	Common	Form 4 ↗
John Oyler	Director	2026-07-21	D	2,340	320	748,936	Common	Form 4 ↗
John Oyler	Director	2026-07-21	D	15,807	319	5,047,019	Common	Form 4 ↗
John Oyler	Director	2026-07-21	D	20,029	317	6,347,340	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-22	D	6,370	0	0	Derivative, Class A Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-22	D	8,645	0	0	Derivative, Class A Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-22	D	6,682	0	0	Derivative, Class A Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-22	D	1,669	325	542,425	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-22	A	490	159	77,925	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-22	A	665	213	141,858	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-22	A	514	194	99,958	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-07-30	D	1,044	324	337,932	Common	Form 4 ↗
Aaron Rosenberg	Chief Financial Officer	2026-08-03	D	1,157	313	361,811	Common	Form 4 ↗
John Oyler	Director	2026-08-10	D	6,717	355	2,383,028	Common	Form 4 ↗
John Oyler	Director	2026-08-10	D	15,869	358	5,675,864	Common	Form 4 ↗
John Oyler	Director	2026-08-10	D	3,476	356	1,236,261	Common	Form 4 ↗
John Oyler	Director	2026-08-10	D	12,418	357	4,428,482	Common	Form 4 ↗
John Oyler	Director	2026-08-10	D	3,680	361	1,327,130	Common	Form 4 ↗
John Oyler	Director	2026-08-10	D	21,254	360	7,640,826	Common	Form 4 ↗
John Oyler	Director	2026-08-10	D	45,044	359	16,157,076	Common	Form 4 ↗
John Oyler	Director	2026-08-10	D	3,673	353	1,297,741	Common	Form 4 ↗
John Oyler	Director	2026-08-10	D	2,813	352	989,603	Common	Form 4 ↗
John Oyler	Director	2026-08-10	D	67	350	23,450	Common	Form 4 ↗
John Oyler	Director	2026-08-11	D	13,403	363	4,871,344	Common	Form 4 ↗
John Oyler	Director	2026-08-11	D	13,695	359	4,920,844	Common	Form 4 ↗
John Oyler	Director	2026-08-11	D	3,176	365	1,160,079	Common	Form 4 ↗
John Oyler	Director	2026-08-11	D	4	367	1,468	Common	Form 4 ↗
John Oyler	Director	2026-08-11	D	1,200	366	439,574	Common	Form 4 ↗
John Oyler	Director	2026-08-11	D	11,568	362	4,191,548	Common	Form 4 ↗
John Oyler	Director	2026-08-11	D	14,569	361	5,266,268	Common	Form 4 ↗
John Oyler	Director	2026-08-11	D	8,081	360	2,911,849	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-08-11	D	10,556	0	0	Derivative, Class A Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-08-11	A	796	159	126,588	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-08-11	D	10,348	0	0	Derivative, Class A Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-08-11	D	13,754	0	0	Derivative, Class A Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-08-11	D	2,666	360	959,760	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-08-11	A	1,058	213	225,693	Common	Form 4 ↗
Chan Lee	SVP, General Counsel	2026-08-11	A	812	194	157,910	Common	Form 4 ↗
John Oyler	Director	2026-08-11	D	5,211	364	1,898,442	Common	Form 4 ↗
John Oyler	Director	2026-08-12	D	15,396	358	5,506,147	Common	Form 4 ↗
John Oyler	Director	2026-08-12	D	1,980	355	702,320	Common	Form 4 ↗
John Oyler	Director	2026-08-12	D	14,102	359	5,064,252	Common	Form 4 ↗
John Oyler	Director	2026-08-12	D	20,899	358	7,490,448	Common	Form 4 ↗
John Oyler	Director	2026-08-12	D	2,515	356	896,426	Common	Form 4 ↗

Sources (244 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

Section 01, Lai Wang. DEF 14A, filed 2026-04-28. Section “Executive Compensation”. As printed: 18,319,310. View filing ↗
Section 01, John Oyler. DEF 14A, filed 2026-04-28. Section “Executive Compensation”. As printed: 17,943,521. View filing ↗
Section 01, Xiaobin Wu. DEF 14A, filed 2026-04-28. Section “Executive Compensation”. As printed: 12,029,451. View filing ↗
Section 01, Aaron Rosenberg. DEF 14A, filed 2026-04-28. Section “Executive Compensation”. As printed: 6,428,374. View filing ↗
Section 01, Chan Lee. DEF 14A, filed 2026-04-28. Section “Executive Compensation”. As printed: 5,055,306. View filing ↗
Section 03, Aaron Rosenberg PSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Aaron Rosenberg RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Lai Wang PSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Lai Wang RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Lai Wang OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Chan Lee PSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Lai Wang RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Chan Lee RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, John Oyler OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Chan Lee OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Aaron Rosenberg OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 08, Dr. Xiaodong Wang. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 4,249,830. View filing ↗
Section 08, Anthony C. Hooper. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 528,129. View filing ↗
Section 08, Shalini Sharp. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 525,165. View filing ↗
Section 08, Dr. Margaret Dugan. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 514,788. View filing ↗
Section 08, Dr. Corazon (Corsee) D. Sanders. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 502,288. View filing ↗
Section 08, Dr. Alessandro Riva. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 494,788. View filing ↗
Section 08, Dr. Olivier Brandicourt. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 492,288. View filing ↗
Section 08, Ranjeev Krishana. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 489,788. View filing ↗
Section 08, Qingqing Yi. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 489,788. View filing ↗
Section 08, Michael Goller. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 484,788. View filing ↗
Section 08, John V. Oyler. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
Section 08, Ms. Elizabeth F. Mooney. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: —. View filing ↗
Section 08, Dr. Felix J. Baker. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: —. View filing ↗
Section 08, Dr. Charles L. Sawyers. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: —. View filing ↗
Section 02, Chan Lee 2026-05-13. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-05-13. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-05-13. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-05-13. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-05-13. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-05-13. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-05-13. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Dr. Alessandro Riva 2026-05-22. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, BAKER BROS. ADVISORS LP 2026-05-22. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Dr. Corazon (Corsee) D. Sanders 2026-05-22. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, BAKER BROS. ADVISORS LP 2026-05-22. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Dr. Margaret Dugan 2026-05-22. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, BAKER BROS. ADVISORS LP 2026-05-22. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, BAKER BROS. ADVISORS LP 2026-05-22. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Qingqing Yi 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Xiaobin Wu 2026-06-08. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Lai Wang 2026-06-08. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-06-08. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Lai Wang 2026-06-08. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-06-08. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Titus B. Ball 2026-06-08. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Xiaobin Wu 2026-06-08. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Titus B. Ball 2026-06-08. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-06-08. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-06-08. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Xiaobin Wu 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Titus B. Ball 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, BAKER BROS. ADVISORS LP 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Xiaodong Wang 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Titus B. Ball 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Dr. Alessandro Riva 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Ms. Elizabeth F. Mooney 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Aaron Rosenberg 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Titus B. Ball 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Anthony C. Hooper 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, BAKER BROS. ADVISORS LP 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Dr. Olivier Brandicourt 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Lai Wang 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Lai Wang 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Xiaobin Wu 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Aaron Rosenberg 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Aaron Rosenberg 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Dr. Charles L. Sawyers 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Lai Wang 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Shalini Sharp 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Xiaodong Wang 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Dr. Margaret Dugan 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Xiaobin Wu 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Lai Wang 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Xiaobin Wu 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Xiaobin Wu 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Lai Wang 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-07-08. Form 4, filed 2026-07-10. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-07-08. Form 4, filed 2026-07-10. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-07-08. Form 4, filed 2026-07-10. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-07-08. Form 4, filed 2026-07-10. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-07-08. Form 4, filed 2026-07-10. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-07-08. Form 4, filed 2026-07-10. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-07-08. Form 4, filed 2026-07-10. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-10. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-10. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-10. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-10. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-10. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-10. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-10. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-10. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-10. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-10. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-13. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-13. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-13. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-13. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-13. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-13. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-13. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-13. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-13. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-14. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-14. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-14. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-14. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-14. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-14. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-14. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-14. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-14. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-14. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-17. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-17. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-17. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-17. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-17. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-17. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-17. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-17. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-17. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-17. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-17. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-20. Form 4, filed 2026-07-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-20. Form 4, filed 2026-07-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-20. Form 4, filed 2026-07-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-20. Form 4, filed 2026-07-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-20. Form 4, filed 2026-07-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-20. Form 4, filed 2026-07-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-20. Form 4, filed 2026-07-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-20. Form 4, filed 2026-07-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-20. Form 4, filed 2026-07-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-20. Form 4, filed 2026-07-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-20. Form 4, filed 2026-07-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-21. Form 4, filed 2026-07-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-21. Form 4, filed 2026-07-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-21. Form 4, filed 2026-07-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-21. Form 4, filed 2026-07-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-07-21. Form 4, filed 2026-07-22. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-07-22. Form 4, filed 2026-07-24. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-07-22. Form 4, filed 2026-07-24. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-07-22. Form 4, filed 2026-07-24. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-07-22. Form 4, filed 2026-07-24. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-07-22. Form 4, filed 2026-07-24. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-07-22. Form 4, filed 2026-07-24. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-07-22. Form 4, filed 2026-07-24. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-07-30. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Aaron Rosenberg 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-08-11. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-08-11. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-08-11. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-08-11. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-08-11. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-08-11. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-08-11. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-08-11. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-08-11. Form 4, filed 2026-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-08-11. Form 4, filed 2026-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-08-11. Form 4, filed 2026-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-08-11. Form 4, filed 2026-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-08-11. Form 4, filed 2026-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-08-11. Form 4, filed 2026-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Chan Lee 2026-08-11. Form 4, filed 2026-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-08-11. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-08-12. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-08-12. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-08-12. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-08-12. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John Oyler 2026-08-12. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 06, 2026 vote. Form 8-K, filed 2026-06-11. Item 5.07 · say-on-pay result. As reported: 94.86% (votes for as printed: 975,327,100). View filing ↗
Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
Section 09b board cost (computed). Computed. Cash 923,718 + equity 1,798,506 + all other 4,249,830 = 6,972,054, summed across the director compensation table rows.
Exelixis, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. View filing ↗
Incyte Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. View filing ↗
Gilead Sciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Gilead Sciences, Inc.'s own proxy. As printed: 28,437,198. View filing ↗
Amgen Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Amgen Inc.'s own proxy. As printed: 24,693,120. View filing ↗
Biogen Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Biogen Inc.'s own proxy. As printed: 23,646,004. View filing ↗
BioMarin Pharmaceutical, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in BioMarin Pharmaceutical, Inc.'s own proxy. As printed: 21,927,563. View filing ↗
Vertex Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in Vertex Pharmaceuticals Inc.'s own proxy. As printed: 21,144,261. View filing ↗
Moderna, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-16. CEO total compensation as printed in Moderna, Inc.'s own proxy. As printed: 19,932,217. View filing ↗
United Therapeutics Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in United Therapeutics Corporation's own proxy. As printed: 18,038,972. View filing ↗
BeOne Medicines (subject), Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in BeOne Medicines's own proxy. As printed: 17,943,521. View filing ↗
Alnylam Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Alnylam Pharmaceuticals, Inc.'s own proxy. As printed: 14,867,600. View filing ↗
Neurocrine Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Neurocrine Biosciences, Inc.'s own proxy. As printed: 13,448,935. View filing ↗
Regeneron Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Regeneron Pharmaceuticals, Inc.'s own proxy. As printed: 7,280,549. View filing ↗